<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03817567</url>
  </required_header>
  <id_info>
    <org_study_id>SCT200IbmESCC</org_study_id>
    <nct_id>NCT03817567</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>Phase Ib, Open-label, Single-arm, Multicenter Study to Evaluate Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma Progressed Following Treatment With Taxane/Platinum/Fluorouracil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinocelltech Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sinocelltech Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR
      monoclonal antibody（SCT200）in patients with advanced esophageal squamous cell carcinoma
      progressed following treatment with taxane/platinum/fluorouracil.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a open label, single-arm multicenter phase Ib study,and is designed to evaluate
      Objective Response Rate (ORR) in advanced esophageal squamous cell carcinoma progressed
      following treatment with taxane/platinum/fluorouracil treated with anti-EGFR monoclonal
      antibody SCT200.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>one year</time_frame>
    <description>ORR is defined as proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST v1.1 during trial treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>one year</time_frame>
    <description>AE are assessed according to NCI CTCAE v4.03.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>one year</time_frame>
    <description>PFS is defined as the time from first dose of SCT200 until the date of first documentation of progression or date of death, whichever occurs first,according to RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>one year</time_frame>
    <description>DOR is defined as time from the date when a patient first meets the criteria for CR or PR according to RECIST v1.1, until the date that progressive disease (PD) is objectively documented or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>one year</time_frame>
    <description>OS is defined as time from first dose of SCT200 until the date of death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>recombinant anti-EGFR monoclonal antibody（SCT200）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6.0mg/kg QW for 6 weeks, then 8.0mg/kg Q2W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant anti-EGFR monoclonal antibody</intervention_name>
    <description>Experimental: Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.</description>
    <arm_group_label>recombinant anti-EGFR monoclonal antibody（SCT200）</arm_group_label>
    <other_name>SCT200</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females. Aged 18 to 75 years old;

          -  Histologically or cytologically proven squamous cell carcinoma of the esophagus, which
             is locally unresectable or distant metastatic disease;

          -  Disease progressed following standard therapies. Patients has treated with
             taxane/platinum/fluorouracil and/or radiotherapy. Failure of standard therapy ：Disease
             progressed or developed non-tolerable toxicity during or within 3 months after last
             systemic chemotherapy or radical concurrent chemoradiotherapy. For adjuvant
             therapy/neoadjuvant therapy, disease relapse or progression during treatment or within
             6 months after treatment is considered as failure of standard therapy;

          -  According to RECIST 1.1 , patients must have at least one measurable lesion which was
             not treated with local treatment such as radiotherapy. Tumour lesions situated in a
             previously irradiated area which have been demonstrated progression in the lesion, are
             considered measurable;

          -  With an Eastern Cooperative Oncology Group (ECOG) performance status 0-1;

          -  Life expectancy of longer than 3 months ( clinical assessment);

          -  Adequate organ and marrow function as defined below:

        Absolute neutrophil count (ANC) greater than/equal to 1.5×l09/L; Platelets greater
        than/equal to 75×109/L; Hemoglobin greater than/equal to 80g/L; Aspartate aminotransferase
        (AST)/alanine aminotransferase (ALT) less than/equal to 3 times ULN, or less than/equal to
        5 times ULN if known liver metastases; Total bilirubin less than/equal to 1.5 within
        institutional limit of normal (ULN); Serum creatinine less than/equal to 1.5 times ULN;
        Electrolyte: magnesium greater than/equal to normal.

          -  Women of childbearing potential must not be pregnant as assessed by a negative urine
             or serum beta HCG test upon admission to the hospital, and must agree to use adequate
             contraception during the study until to 6 months after the last dose of SCT200.For
             male,if his sexual partners is child-bearing potential, he should use effective
             contraception from the time of signing the informed consent form until at least 6
             months after the last dose of study drug.

          -  Able to provide written informed consent and can understand and comply with the
             requirements of the study;

        Exclusion Criteria:

          -  Patients with active central nervous system metastasis or a history of central nervous
             system metastasis;(If the subject has been suspected with central nervous system
             metastasis,imaging examination confirmation must be performed within 28 days to
             exclude central nervous system metastasis;

          -  Patients with other primary malignancies except cured of non-melanoma skin cancer,
             carcinoma in situ of cervix or prostatic intraepithelial neoplasia;

          -  Patients who are allergic to analogue of SCT200 and/or its inactive ingredients;

          -  Patients administrated EGFR target treatment including EGFR TKI agent or anti- EGFR
             monoclonal antibody;

          -  Within 4 weeks, patients received anti-tumor drugs (such as chemotherapy, hormone
             therapy, immune therapy, the antibody therapy, radiotherapy) or research drugs, or
             patients with grade 2 or more adverse reaction caused by previous anti-tumor
             therapy(except alopecia or neurotoxicity grade 2 or less);

          -  Patients are currently enrolled in other research devices or in research drugs, or
             less than 4 weeks from other research drugs or devices;

          -  Patients received major surgery(such as need general anesthesia ) within 4 weeks ,
             should recover from the injury associated with the surgery;

          -  Patients treated with EPO, G-CSF or GM-CSF;

          -  Patients who have clinically significant cardiovascular disease (defined as unstable
             angina pectoris, symptomatic congestive heart failure (NYHA, greater than II),
             uncontrollable severe arrhythmia);

          -  Patients occurred myocardial infarction within 6 months;

          -  Patients who have interstitial lung disease, such as interstitial pneumonia, pulmonary
             fibrosis, or CT or MRI reminder ILD ;

          -  Patients with clinical symptoms, required clinical intervention or stable time less
             than 4 weeks of serous cavity effusion (such as pleural effusion and ascites);

          -  Patients with active hepatitis B or active hepatitis C, etc. (for patients with a
             history of hepatitis B, whether treated or not, HBV DNA ≥104 or ≥ 2000IU/ml, HCV
             RNA≥15IU/ml); HIV antibody positive (if there is no clinical evidence suggesting that
             there may be HIV infection, there is no need to detect);

          -  Patients with uncontrolled active infections before enrollment 2 weeks (except simple
             urinary tract infection or upper respiratory tract infection);

          -  Patients have alcohol or drug addiction;

          -  Patients with serious abnormal medical, psychological or laboratory results history
             which may affect explanation of study results;

          -  Subjects are considered not suitable for the study by investigator,who have other
             conditions that may affect their adherence and the evaluation of study indicators.,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Foxiao Qiao, Ph D</last_name>
    <phone>18911165421</phone>
    <phone_ext>86-10-58628288</phone_ext>
    <email>Foxiao_qiao@sinocelltech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>yuxian bai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital.</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>kai zang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>wei li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>yi ba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>January 15, 2019</study_first_submitted>
  <study_first_submitted_qc>January 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2019</study_first_posted>
  <last_update_submitted>January 24, 2019</last_update_submitted>
  <last_update_submitted_qc>January 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinoma</keyword>
  <keyword>Carcinoma, Squamous Cell</keyword>
  <keyword>Esophageal Neoplasms</keyword>
  <keyword>Neoplasms, Squamous Cell</keyword>
  <keyword>Esophageal Diseases</keyword>
  <keyword>Epidermal growth factor receptor</keyword>
  <keyword>EGFR</keyword>
  <keyword>SCT200</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

